50720 Federal Register / Vol. 86, No. 173 / Friday, September 10, 2021 / Notices 

within 30-days of the date of this 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: 

Amy Williams, Director of the Office of 

Advocacy Relations (OAR), NCI, NIH, 

31 Center Drive, Bldg. 31, Room 10A28, 

MSC 2580, Bethesda, MD 20892, call 

non-toll-free number 240–781–3406, or 

email your request, including your 

address, to amy.williams@nih.gov. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on October 8, 2020, page 63565 

(Vol. 85 FR 63565) and allowed 60 days 

for public comment. No public 

comments were received. The National 

Cancer Institute (NCI), National 

Institutes of Health, may not conduct or 

sponsor, and the respondent is not 

required to respond to, an information 

collection that has been extended, 

revised, or implemented on or after 

October 1, 1995, unless it displays a 

currently valid OMB control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. 

Proposed Collection: Stakeholder 

Measures and Advocate Forms at the 

National Cancer Institute (NCI), OMB 

#0925–NEW: Expiration Date XX/XX/ 

XXXX, NEW, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The Office of Advocacy 

Relations (OAR) has collected data from 

different stakeholder constituencies: 

NIH and NCI staff, NCI-funded scientists 

and staff from universities and cancer 

centers, research advocates and their 

advocacy organizations, and members of 

scientific and professional societies and 

their organizations concerned about 

cancer. OAR uses the Profile 

Completion Questionnaire to capture 

applicant information such as basic 

contact information, age, gender, race 

and ethnicity, work focus, employment 

status, health experiences, and research 

advocacy experience. In addition, a 

post-activity survey is requested to 

ensure the advocates received property 

support by assessing satisfaction, 

expectations, involvement, barriers, and 

recruitment while working with the 

NCI. OAR continues to use the database 

system, which will allow this 

information to be collected 

electronically to match advocates easily 

and appropriately to NCI initiatives and 

activities as well as to assist NCI 

researchers in finding advocates to 

support their activities. In the previous 

three years, OAR has welcomed 49 

advocates into our network. Advocates 

have contributed to over 30 activities, 

ranging widely in scope and duration. 

Several examples include speaking 

engagements, Task Force appointments, 

Steering Committee appointments, 

webinars, Advisory Board 

appointments, etc. These forms were 

previously approved as, ‘‘Generic 

Submission for Formative Research, Pretesting, Stakeholder Measures and 

Advocate Forms at NCI’’ (OMB #: 0925– 

0641, Expiration Date: 1/31/2021). 

However, since OAR has not submitted 

Gen ICs for the past approvals this is 

being submitted as a new submission. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

16. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

time per 

response 

(in hours) 

Total annual 

burden hour 

Profile Completion ............................. Individuals ........................................ 30 1 30/60 15 

Survey ............................................... Individuals ........................................ 15 1 5/60 1 

Totals ......................................... ........................................................... ........................ 45 ........................ 16 

Dated: September 2, 2021. 

Diane Kreinbrink, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2021–19544 Filed 9–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, NIDA. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in sections 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

NATIONAL INSTITUTE ON DRUG 

ABUSE, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, NIDA. 

Date: October 26, 2021. 

Time: 8:00 a.m. to 5:15 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institute on Drug Abuse, 

NIH, Biomedical Research Center, 251 

Bayview Boulevard, Baltimore, MD 21224 

(Virtual Meeting). 

Contact Person: Deon M. Harvey, Ph.D., 

Management Analyst, Office of the Scientific 

Director, National Institute on Drug Abuse, 

251 Bayview Boulevard, Room 04A314, 

Baltimore, MD 21224, (443) 740–2466, 

deon.harvey@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 173 / Friday, September 10, 2021 / Notices 50721 

Dated: September 3, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–19533 Filed 9–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Acute Renal Injury 

Sequelae in NICU Graduates (ARISING). 

Date: October 15, 2021. 

Time: 1:00 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7345, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 7, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–19559 Filed 9–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–20– 

131: Mammalian Models for Translational 

Research. 

Date: October 4, 2021. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jeffrey Smiley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6194, 

MSC 7804, Bethesda, MD 20892, 301–272– 

4596, smileyja@csr.nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Social Sciences and Population Studies: A 

Study Section. 

Date: October 5–6, 2021. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Suzanne Ryan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3139, 

MSC 7770, Bethesda, MD 20892, (301) 435– 

1712, ryansj@csr.nih.gov. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Musculoskeletal Tissue Engineering Study 

Section. 

Date: October 12–13, 2021. 

Time: 9:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Srikanth Ranganathan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4214, 

MSC 7802, Bethesda, MD 20892, (301) 435– 

1787, srikanth.ranganathan@nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Development—2 

Study Section. 

Date: October 12–13, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rass M. Shayiq, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, (301) 435– 

2359, shayiqr@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Clinical Neuroscience and 

Neurodegeneration Study Section. 

Date: October 13–14, 2021. 

Time: 8:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Alessandra C. Rovescalli, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 5205, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1021, rovescaa@mail.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Clinical Neuroimmunology and Brain 

Tumors Study Section. 

Date: October 14–15, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Aleksey Gregory 

Kazantsev, Scientific Review Officer, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5201, 

Bethesda, MD 20817, 301–435–1042, 

aleksey.kazantsev@nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Pathogenic Eukaryotes Study Section. 

Date: October 14–15, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Tera Bounds, DVM, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3198, 

MSC 7808, Bethesda, MD 20892, 301–435– 

2306, boundst@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 19– 

367: Maximizing Investigators’ Research 

Award. 

Date: October 14–15, 2021. 

Time: 10:00 a.m. to 8:00 p.m. 


jbell on DSKJLSW7X2PROD with NOTICES